Triple Therapy Enhances Glycemic Control in Cystic Fibrosis Patients with Abnormal Glucose Tolerance
Highlight
The triple combination therapy of elexacaftor-tezacaftor-ivacaftor significantly reduces 2-hour post-oral glucose tolerance test blood glucose levels in cystic fibrosis (CF) patients with impaired glucose regulation. It also lowers hemoglobin A1c (A1c) and sweat chloride concentrations, indicating improved glycemic control and enhanced CF transmembrane conductance regulator (CFTR) function. The treatment is well tolerated, with predominantly mild or moderate adverse events reported.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.